tiprankstipranks
Trending News
More News >
Replimune Group Inc (REPL)
NASDAQ:REPL
US Market
Advertisement

Replimune Group (REPL) Stock Forecast & Price Target

Compare
367 Followers
See the Price Targets and Ratings of:

REPL Analyst Ratings

Hold
9Ratings
Hold
1 Buy
7 Hold
1 Sell
Based on 9 analysts giving stock ratings to
Replimune
Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

REPL Stock 12 Month Forecast

Average Price Target

$4.29
▲(36.19%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $4.29 with a high forecast of $9.00 and a low forecast of $2.00. The average price target represents a 36.19% change from the last price of $3.15.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","14":"$14","4.25":"$4.25","7.5":"$7.5","10.75":"$10.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.25,7.5,10.75,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,9.138461538461538,9.126923076923077,9.115384615384615,9.103846153846154,9.092307692307692,9.080769230769231,9.069230769230769,9.057692307692308,9.046153846153846,9.034615384615385,9.023076923076923,9.011538461538462,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,8.776153846153846,8.402307692307692,8.028461538461539,7.654615384615385,7.280769230769231,6.906923076923077,6.533076923076923,6.159230769230769,5.785384615384615,5.411538461538461,5.037692307692308,4.663846153846154,{"y":4.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,8.6,8.05,7.5,6.95,6.4,5.85,5.3,4.75,4.2,3.6500000000000004,3.0999999999999996,2.55,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.73,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.27,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$9.00Average Price Target$4.29Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on REPL
Evan SeigermanBMO Capital
BMO Capital
$27$2
Sell
-36.51%
Downside
Downgraded
07/23/25
Replimune Group (REPL) was downgraded to a Sell Rating at BMO Capital
Leerink Partners Analyst forecast on REPL
Jonathan ChangLeerink Partners
Leerink Partners
$21$3
Hold
-4.76%
Downside
Downgraded
07/23/25
Replimune Group (REPL) Receives a Buy from Leerink PartnersLeerink Partners analyst Jonathan Chang reiterated an Outperform rating and $21.00 price target on Replimune Group (NASDAQ: REPL)
H.C. Wainwright Analyst forecast on REPL
Robert BurnsH.C. Wainwright
H.C. Wainwright
Hold
Downgraded
07/23/25
Replimune Group (REPL) was downgraded to a Hold Rating at H.C. WainwrightValuation and Risks. We originally utilized a discounted cash flow (DCF)-based methodology to value Replimune shares. Our core assumptions currently comprise a 12% discount rate, a 29% effective tax rate, and a 50% probability of approval for RP1 in anti-PD1 failed melanoma patients.
Piper Sandler Analyst forecast on REPL
Allison BratzelPiper Sandler
Piper Sandler
$22$3
Hold
-4.76%
Downside
Downgraded
07/22/25
Replimune downgraded to Neutral from Overweight at Piper SandlerReplimune downgraded to Neutral from Overweight at Piper Sandler
Wedbush
$19$4
Hold
26.98%
Upside
Downgraded
07/22/25
Replimune downgraded to Neutral from Outperform at WedbushReplimune downgraded to Neutral from Outperform at Wedbush
J.P. Morgan Analyst forecast on REPL
Anupam RamaJ.P. Morgan
J.P. Morgan
$19$9
Hold
185.71%
Upside
Downgraded
07/22/25
Replimune downgraded to Neutral from Overweight at JPMorganReplimune downgraded to Neutral from Overweight at JPMorgan
Barclays Analyst forecast on REPL
Peter LawsonBarclays
Barclays
$17$3
Hold
-4.76%
Downside
Downgraded
07/22/25
Barclays Remains a Buy on Replimune Group (REPL)Barclays analyst Peter Lawson reiterated an Overweight rating and $17.00 price target on Replimune Group (NASDAQ: REPL).
Jefferies Analyst forecast on REPL
Roger SongJefferies
Jefferies
$31$6
Buy
90.48%
Upside
Reiterated
07/22/25
Replimune price target lowered to $6 from $31 at JefferiesReplimune price target lowered to $6 from $31 at Jefferies
Cantor Fitzgerald Analyst forecast on REPL
Li WatsekCantor Fitzgerald
Cantor Fitzgerald
Hold
Downgraded
07/22/25
Replimune downgraded to Neutral from Overweight at Cantor FitzgeraldReplimune downgraded to Neutral from Overweight at Cantor Fitzgerald
Roth MKM
$17
Buy
439.68%
Upside
Reiterated
09/09/24
Roth/MKM reiterates Buy Rating on Replimune Group (REPL)Roth/MKM analyst Ben Paluch reiterated a Buy rating and $17.00 price target on Replimune Group (NASDAQ: REPL).
Rodman & Renshaw Analyst forecast on REPL
Anthony ButlerRodman & Renshaw
Rodman & Renshaw
$12
Buy
280.95%
Upside
Initiated
08/08/24
Replimune Group initiated with a Buy at Rodman & RenshawReplimune Group initiated with a Buy at Rodman & Renshaw
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on REPL
Evan SeigermanBMO Capital
BMO Capital
$27$2
Sell
-36.51%
Downside
Downgraded
07/23/25
Replimune Group (REPL) was downgraded to a Sell Rating at BMO Capital
Leerink Partners Analyst forecast on REPL
Jonathan ChangLeerink Partners
Leerink Partners
$21$3
Hold
-4.76%
Downside
Downgraded
07/23/25
Replimune Group (REPL) Receives a Buy from Leerink PartnersLeerink Partners analyst Jonathan Chang reiterated an Outperform rating and $21.00 price target on Replimune Group (NASDAQ: REPL)
H.C. Wainwright Analyst forecast on REPL
Robert BurnsH.C. Wainwright
H.C. Wainwright
Hold
Downgraded
07/23/25
Replimune Group (REPL) was downgraded to a Hold Rating at H.C. WainwrightValuation and Risks. We originally utilized a discounted cash flow (DCF)-based methodology to value Replimune shares. Our core assumptions currently comprise a 12% discount rate, a 29% effective tax rate, and a 50% probability of approval for RP1 in anti-PD1 failed melanoma patients.
Piper Sandler Analyst forecast on REPL
Allison BratzelPiper Sandler
Piper Sandler
$22$3
Hold
-4.76%
Downside
Downgraded
07/22/25
Replimune downgraded to Neutral from Overweight at Piper SandlerReplimune downgraded to Neutral from Overweight at Piper Sandler
Wedbush
$19$4
Hold
26.98%
Upside
Downgraded
07/22/25
Replimune downgraded to Neutral from Outperform at WedbushReplimune downgraded to Neutral from Outperform at Wedbush
J.P. Morgan Analyst forecast on REPL
Anupam RamaJ.P. Morgan
J.P. Morgan
$19$9
Hold
185.71%
Upside
Downgraded
07/22/25
Replimune downgraded to Neutral from Overweight at JPMorganReplimune downgraded to Neutral from Overweight at JPMorgan
Barclays Analyst forecast on REPL
Peter LawsonBarclays
Barclays
$17$3
Hold
-4.76%
Downside
Downgraded
07/22/25
Barclays Remains a Buy on Replimune Group (REPL)Barclays analyst Peter Lawson reiterated an Overweight rating and $17.00 price target on Replimune Group (NASDAQ: REPL).
Jefferies Analyst forecast on REPL
Roger SongJefferies
Jefferies
$31$6
Buy
90.48%
Upside
Reiterated
07/22/25
Replimune price target lowered to $6 from $31 at JefferiesReplimune price target lowered to $6 from $31 at Jefferies
Cantor Fitzgerald Analyst forecast on REPL
Li WatsekCantor Fitzgerald
Cantor Fitzgerald
Hold
Downgraded
07/22/25
Replimune downgraded to Neutral from Overweight at Cantor FitzgeraldReplimune downgraded to Neutral from Overweight at Cantor Fitzgerald
Roth MKM
$17
Buy
439.68%
Upside
Reiterated
09/09/24
Roth/MKM reiterates Buy Rating on Replimune Group (REPL)Roth/MKM analyst Ben Paluch reiterated a Buy rating and $17.00 price target on Replimune Group (NASDAQ: REPL).
Rodman & Renshaw Analyst forecast on REPL
Anthony ButlerRodman & Renshaw
Rodman & Renshaw
$12
Buy
280.95%
Upside
Initiated
08/08/24
Replimune Group initiated with a Buy at Rodman & RenshawReplimune Group initiated with a Buy at Rodman & Renshaw
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Replimune Group

1 Month
xxx
Success Rate
17/22 ratings generated profit
77%
Average Return
+2.70%
downgraded a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 77.27% of your transactions generating a profit, with an average return of +2.70% per trade.
3 Months
xxx
Success Rate
11/22 ratings generated profit
50%
Average Return
-2.69%
downgraded a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -2.69% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
9/22 ratings generated profit
41%
Average Return
-21.54%
downgraded a sell rating 4 days ago
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 40.91% of your transactions generating a profit, with an average return of -21.54% per trade.
2 Years
xxx
Success Rate
1/11 ratings generated profit
9%
Average Return
-52.93%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 9.09% of your transactions generating a profit, with an average return of -52.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REPL Analyst Recommendation Trends

Rating
Jan 25
Feb 25
May 25
Jun 25
Jul 25
Strong Buy
6
7
12
14
16
Buy
9
8
7
8
3
Hold
1
0
0
0
7
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
16
15
19
22
27
In the current month, REPL has received 19 Buy Ratings, 7 Hold Ratings, and 1 Sell Ratings. REPL average Analyst price target in the past 3 months is 4.29.
Each month's total comprises the sum of three months' worth of ratings.

REPL Financial Forecast

REPL Earnings Forecast

Next quarter’s earnings estimate for REPL is -$0.79 with a range of -$0.93 to -$0.56. The previous quarter’s EPS was -$0.82. REPL beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.96% of the time in the same period. In the last calendar year REPL has Outperformed its overall industry.
Next quarter’s earnings estimate for REPL is -$0.79 with a range of -$0.93 to -$0.56. The previous quarter’s EPS was -$0.82. REPL beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.96% of the time in the same period. In the last calendar year REPL has Outperformed its overall industry.
No data currently available

REPL Sales Forecast

Next quarter’s sales forecast for REPL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. REPL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.43% of the time in the same period. In the last calendar year REPL has Preformed in-line its overall industry.
Next quarter’s sales forecast for REPL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. REPL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.43% of the time in the same period. In the last calendar year REPL has Preformed in-line its overall industry.

REPL Stock Forecast FAQ

What is REPL’s average 12-month price target, according to analysts?
Based on analyst ratings, Replimune Group Inc’s 12-month average price target is 4.29.
    What is REPL’s upside potential, based on the analysts’ average price target?
    Replimune Group Inc has 36.19% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is REPL a Buy, Sell or Hold?
          Replimune Group Inc has a consensus rating of Hold which is based on 1 buy ratings, 7 hold ratings and 1 sell ratings.
            What is Replimune Group Inc’s price target?
            The average price target for Replimune Group Inc is 4.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $9.00 ,the lowest forecast is $2.00. The average price target represents 36.19% Increase from the current price of $3.15.
              What do analysts say about Replimune Group Inc?
              Replimune Group Inc’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of REPL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis